Home / Market Reports / Pharma & Healthcare
/ Global Drugs for Malaria Market Growth (Status and Outlook) 2023-2029
Global Drugs for Malaria Market Growth (Status and Outlook) 2023-2029
Product Code:453177
Published Date: Feb 08,2023
Pages: 89
Region: Global
Category: Pharma & Healthcare
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
LPI (LP Information)' newest research report, the “Drugs for Malaria Industry Forecast” looks at past sales and reviews total world Drugs for Malaria sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Malaria sales for 2023 through 2029. With Drugs for Malaria sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Malaria industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Malaria landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Malaria portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Malaria market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Malaria and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Malaria.
The global Drugs for Malaria market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Malaria market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Segmentation by application
Prevention
Treatment
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma